CN113195471A - 多取代吡啶酮类衍生物及其在医药上的应用 - Google Patents

多取代吡啶酮类衍生物及其在医药上的应用 Download PDF

Info

Publication number
CN113195471A
CN113195471A CN201980070724.4A CN201980070724A CN113195471A CN 113195471 A CN113195471 A CN 113195471A CN 201980070724 A CN201980070724 A CN 201980070724A CN 113195471 A CN113195471 A CN 113195471A
Authority
CN
China
Prior art keywords
alkyl
fluorophenyl
oxo
compound
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980070724.4A
Other languages
English (en)
Other versions
CN113195471B (zh
Inventor
段茂圣
刘佳乐
田世鸿
邓伟
严超
赵乐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Puhe Pharmaceutical Technology Co ltd
Original Assignee
Beijing Yuezhikangtai Biomedicines Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Yuezhikangtai Biomedicines Co ltd filed Critical Beijing Yuezhikangtai Biomedicines Co ltd
Publication of CN113195471A publication Critical patent/CN113195471A/zh
Application granted granted Critical
Publication of CN113195471B publication Critical patent/CN113195471B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

公开了多取代吡啶酮类衍生物及其在医药上的应用。特别地，公开了涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其用作酪氨酸激酶抑制剂的用途，特别是用于治疗与酪氨酸激酶活性相关的疾病的用途。其中通式(I)中的各取代基的定义与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN201980070724.4A 2018-08-27 2019-04-10 多取代吡啶酮类衍生物及其在医药上的应用 Active CN113195471B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018109795252 2018-08-27
CN201810979525 2018-08-27
PCT/CN2019/081987 WO2020042618A1 (zh) 2018-08-27 2019-04-10 多取代吡啶酮类衍生物及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN113195471A true CN113195471A (zh) 2021-07-30
CN113195471B CN113195471B (zh) 2023-05-02

Family

ID=69645015

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980070724.4A Active CN113195471B (zh) 2018-08-27 2019-04-10 多取代吡啶酮类衍生物及其在医药上的应用

Country Status (7)

Country Link
US (1) US20210355107A1 (zh)
EP (1) EP3845527A4 (zh)
KR (1) KR20210066820A (zh)
CN (1) CN113195471B (zh)
AU (1) AU2019331934A1 (zh)
CA (1) CA3114987A1 (zh)
WO (1) WO2020042618A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787144A (zh) * 2019-09-26 2022-07-22 埃克塞里艾克西斯公司 吡啶酮化合物及用于调节蛋白激酶的方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4029862A4 (en) * 2019-09-06 2023-10-04 Shanghai Institute of Materia Medica, Chinese Academy of Sciences CONNECTION WITH AXL AND C-MET KINASE INHIBITORY ACTIVITY, THEIR PREPARATION AND USE
CN117362275A (zh) * 2022-06-29 2024-01-09 广州百霆医药科技有限公司 一种酪氨酸蛋白激酶抑制剂及其用途
CN117486860A (zh) * 2022-07-25 2024-02-02 上海博悦生物科技有限公司 Axl&c-Met双重抑制剂、制备方法以及用途
CN116874420B (zh) * 2023-06-25 2024-03-26 山东轩德医药科技有限公司 一种乐伐替尼中间体4-氯-7-甲氧基喹啉-6-酰胺的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101005843A (zh) * 2004-06-28 2007-07-25 布里斯托尔-迈尔斯·斯奎布公司 吡咯并三嗪激酶抑制剂
CN101128199A (zh) * 2004-04-23 2008-02-20 布里斯托尔-迈尔斯斯奎布公司 作为激酶抑制剂的单环杂环
CN101528702A (zh) * 2006-06-08 2009-09-09 阿雷生物药品公司 喹啉化合物和使用方法
WO2012006960A1 (en) * 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011001763A1 (ja) 2009-06-29 2011-01-06 パナソニック電工株式会社 熱可塑性樹脂組成物、熱可塑性樹脂組成物の製造方法、成形品、携帯電話機用卓上ホルダー、携帯電話機の内部シャーシ部品、電子機器用筐体及び電子機器用内部部品
KR20140090678A (ko) * 2011-11-14 2014-07-17 세파론, 인코포레이티드 AXL 및 c-MET 키나제 억제제로서의 우라실 유도체
ES2749726T3 (es) * 2014-12-25 2020-03-23 Ono Pharmaceutical Co Derivado de quinolina

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128199A (zh) * 2004-04-23 2008-02-20 布里斯托尔-迈尔斯斯奎布公司 作为激酶抑制剂的单环杂环
CN101005843A (zh) * 2004-06-28 2007-07-25 布里斯托尔-迈尔斯·斯奎布公司 吡咯并三嗪激酶抑制剂
CN101528702A (zh) * 2006-06-08 2009-09-09 阿雷生物药品公司 喹啉化合物和使用方法
WO2012006960A1 (en) * 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787144A (zh) * 2019-09-26 2022-07-22 埃克塞里艾克西斯公司 吡啶酮化合物及用于调节蛋白激酶的方法

Also Published As

Publication number Publication date
EP3845527A1 (en) 2021-07-07
EP3845527A4 (en) 2022-06-08
KR20210066820A (ko) 2021-06-07
CN113195471B (zh) 2023-05-02
CA3114987A1 (en) 2020-03-05
AU2019331934A1 (en) 2021-05-06
US20210355107A1 (en) 2021-11-18
WO2020042618A1 (zh) 2020-03-05

Similar Documents

Publication Publication Date Title
CN110627796B (zh) 含氮杂环类衍生物及其在医药上的应用
CN113195471B (zh) 多取代吡啶酮类衍生物及其在医药上的应用
CN112368283B (zh) 含二并环类衍生物抑制剂、其制备方法和应用
KR20220027879A (ko) 질소 함유 헤테로사이클릭 유도체의 조절제, 이의 제조방법 및 용도
JP6203439B2 (ja) テトラヒドロピラニルメチル基を有するピリドン誘導体
CN111295384A (zh) 双环类衍生物抑制剂、其制备方法和应用
JP5689069B2 (ja) ピラゾロピリジンｐｉ３ｋ阻害剤化合物及び使用方法
CN110520416B (zh) 多取代吡啶酮类衍生物、其制备方法及其医药用途
JP7384536B2 (ja) キナゾリン化合物並びにその調製方法、使用及び医薬組成物
JP7254094B2 (ja) Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体
EP4194441A1 (en) Nitroxoline derivative, preparation method therefor, and use thereof
WO2013053273A1 (zh) 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
EP3888652A1 (en) Heterocyclic compound
TWI705965B (zh) 新穎三環化合物
JP2023509155A (ja) ビフェニル系誘導体阻害剤、その調製方法及び使用
WO2022100738A1 (zh) 含二并环类衍生物抑制剂自由碱的晶型及其制备方法和应用
CN115836064A (zh) 具有egfr抑制活性的三嗪衍生物及其制备方法和应用
TW202241862A (zh) 二甲醯胺類化合物、其製備方法及其在醫藥上的應用
WO2023174406A1 (zh) 含氮杂环类衍生物抑制剂、其制备方法和应用
WO2024067714A1 (zh) 具有抗kras突变肿瘤活性的化合物
WO2024041606A1 (zh) 具有抗kras突变肿瘤活性的化合物
WO2021057782A1 (zh) 杂环衍生物及其用途
TW202136259A (zh) 聯苯類衍生物抑制劑及其製備方法和應用
CN117800976A (zh) 一类含氮杂环类化合物、制备方法和用途
CN116143805A (zh) 一类含氮杂环联芳基类化合物、制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20221207

Address after: 215124 Floor 19, Building 1, Tianyun Plaza, No. 111, Wusongjiang Avenue, Guoxiang Street, Wuzhong District, Suzhou, Jiangsu

Applicant after: Suzhou Puhe Pharmaceutical Technology Co.,Ltd.

Address before: 102200 3rd floor, building 1, 29 shengshengyuan Road, Huilongguan town, Changping District, Beijing

Applicant before: BEIJING YUEZHIKANGTAI BIOMEDICINES Co.,Ltd.

GR01 Patent grant
GR01 Patent grant